Bighat Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Bighat Biosciences, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include BIGHAT. The owner is based in San Mateo, CA.
1900 Alameda de las Pulgas, Suite 400
San Mateo, CA 94403
Showing of trademarks Trademarks
Trademark Classifications
Bighat Biosciences, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Bighat Biosciences, Inc. have?
Bighat Biosciences, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending, 3 abandoned.
What trademark classes does Bighat Biosciences, Inc. file in?
Bighat Biosciences, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Bighat Biosciences, Inc.'s most well-known trademarks?
Bighat Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as BIGHAT. These are among 1 currently registered trademark in the portfolio.
What is Bighat Biosciences, Inc.'s trademark registration success rate?
Bighat Biosciences, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.